These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37167571)

  • 21. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
    Schettini F; Conte B; Buono G; De Placido P; Parola S; Griguolo G; Fabi A; Bighin C; Riccardi F; Cianniello D; De Laurentiis M; Puglisi F; Pelizzari G; Bonotto M; Russo S; Frassoldati A; Pazzola A; Montemurro F; Lambertini M; Guarneri V; Cognetti F; Locci M; Generali D; Conte P; De Placido S; Giuliano M; Arpino G; Del Mastro L
    ESMO Open; 2021 Apr; 6(2):100099. PubMed ID: 33819752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
    Gümüş M; Davidson N; Bauknecht T; Soldatenkova V; Benhadji KA
    Curr Med Res Opin; 2012 Mar; 28(3):401-13. PubMed ID: 22181343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
    JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
    Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
    J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
    Baselga J; Cortés J; Kim SB; Im SA; Hegg R; Im YH; Roman L; Pedrini JL; Pienkowski T; Knott A; Clark E; Benyunes MC; Ross G; Swain SM;
    N Engl J Med; 2012 Jan; 366(2):109-19. PubMed ID: 22149875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Dang C; Iyengar N; Datko F; D'Andrea G; Theodoulou M; Dickler M; Goldfarb S; Lake D; Fasano J; Fornier M; Gilewski T; Modi S; Gajria D; Moynahan ME; Hamilton N; Patil S; Jochelson M; Norton L; Baselga J; Hudis C
    J Clin Oncol; 2015 Feb; 33(5):442-7. PubMed ID: 25547504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
    Miles D; Baselga J; Amadori D; Sunpaweravong P; Semiglazov V; Knott A; Clark E; Ross G; Swain SM
    Breast Cancer Res Treat; 2013 Nov; 142(1):89-99. PubMed ID: 24129974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
    Cortés J; Baselga J; Im YH; Im SA; Pivot X; Ross G; Clark E; Knott A; Swain SM
    Ann Oncol; 2013 Oct; 24(10):2630-2635. PubMed ID: 23868905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
    Fleeman N; Bagust A; Beale S; Dwan K; Dickson R; Proudlove C; Dundar Y
    Pharmacoeconomics; 2015 Jan; 33(1):13-23. PubMed ID: 25138171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.
    Dai WF; Beca JM; Nagamuthu C; Liu N; de Oliveira C; Earle CC; Trudeau M; Mercer RE; Chan KKW
    JAMA Netw Open; 2022 Feb; 5(2):e2145460. PubMed ID: 35226087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
    Abraham P; Gricar J; Zhang Y; Shankaran V
    Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
    Benedict A; Cameron DA; Corson H; Jones SE
    Pharmacoeconomics; 2009; 27(10):847-59. PubMed ID: 19803539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.
    Swain SM; Im YH; Im SA; Chan V; Miles D; Knott A; Clark E; Ross G; Baselga J
    Oncologist; 2014 Jul; 19(7):693-701. PubMed ID: 24869931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
    Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.
    Gong IY; Yan AT; Earle CC; Trudeau ME; Eisen A; Chan KKW
    Breast Cancer Res Treat; 2020 May; 181(1):155-165. PubMed ID: 32236828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older.
    Brufsky A; Liu X; Li B; McRoy L; Chen C; Layman RM; Rugo HS
    Front Oncol; 2023; 13():1237751. PubMed ID: 37841423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G; Coleman R; Gradishar W
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer.
    Kaufman PA; Neuberger E; Schwartz NRM; Wang S; Liu Y; Hsu LI; Bartley K; Blahna MT; Pittner BT; Wong G; Anders C
    Front Oncol; 2023; 13():1264861. PubMed ID: 37849811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.